The use of a titanium-containing drug for the prevention of severe degrees of radiation mucositis in patients with metal structures in the oral cavity

Introduction. Oral mucositis is one of the earliest and most frequent complications of radiation therapy or chemotherapy in patients diagnosed with oropharyngeal cancer. Because of this pathology, therapeutic interventions are most often used, thereby poor treatment is considered an etiological factor of oral mucositis. Now, this issue is being actively studied in the world, but a unified algorithm for treatment and prevention of oral mucositis has not been formed.

The study objective – is to evaluate the effect of titanium glycerosolvate aquacomplex in reducing the intensity of radiation induced reactions and reducing the frequency of interruptions.

Materials and methods. 52 patients diagnosed with oropharyngeal cancer were included in this study, treated with radiotherapy or chemotherapy. For prophylaxis of severe stages of oral mucositis, 32 patients underwent standard symptomatic therapy (group 1, control group); 20 patients took titanium glycerosolvate aquacomplex in accordance with symptomatic therapy (group 2).

Results. In the group 1 only 61.7 % of patients completed treatment. In the group 2 80 % of patients completely underwent antitumor therapy. At the same time, they developed oral mucositis of the I–II degree. Also, in the group of the studied drug, in 100 % of cases, therapy was performed without interruptions.

Conclusion. Using titanium glycerosolvate aquacomplex for the prophylaxis of severe stages of oral mucositis during radiotherapy or chemotherapy of oropharyngeal cancer is effective and safe. It is also convenient from the medical and economic side, thanks to the ability to use it on an outpatient basis.

1. The state of oncological care to the population of Russia in 2019 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. P.A. Herzen Moscow State Medical Research Institute – branch of the Federal State Budgetary Institution “NMIC of Radiology” of the Ministry of Health of Russia. Moscow, 2020. 239 p. (In Russ.).

2. Polyakov A.P., Reshetov I.V., Boyko A.V. et al. Fifteen-year results of combined treatment of locally advanced malignant tumors of the oropharyngeal zone with simultaneous microsurgical reconstruction. Onkologiya. Zhurnal im. P.A. Gercena = Oncology. P.A. Herzen Journal 2015;4(2):12–9. (In Russ.).

3. Spiotto M.T., Jefferson G., Wenig B. et al. Differences in survival with surgeryand postoperative radiotherapy compared with definitive chemoradiotherapy for oral cavity cancer: a national cancer database analysis. JAMA Otolaryngol Head Neck Surg 2017;143(7):691–9. DOI: 10.1001/jamaoto.2017.0012.

4. Tyulyandin S.A., Nosov D.A., Perevodchikova N.I. Minimum clinical recommendations of the European Society of Medical Oncology (ESMO). Medicinskij alfavit = Medical Alphabet 2014;3(18):59–65. (In Russ.).

5. Gvozdikova E.N., Avanesov A.M., Manuilov B.M. Features of tactics of treatment of oral mucositis in cancer patients on the background of radiation treatment and/or chemotherapy. Novoe v stomatologii = New in Dentistry 2017;5:40–2. (In Russ.).

6. Rubenstein E.B., Peterson D.E., Schubert M. et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004;100(9 Suppl.):2026–46. DOI: 10.1002/cncr.20163.

7. Keefe D.M., Schubert M.M., Elting L.S. et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007;109(5):820–31. DOI: 10.1002/cncr.22484.

8. Lalla R.V., Bowen J., Barasch A. et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014;120(10):1453–61. DOI: 10.1002/cncr.28592.

9. Elad Sh., Cheng K.K., Lalla R.V. et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2020;126: 4423–31. DOI: 10.1002/cncr.33100.